{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
USANA Health Sciences, Inc.
USANA Health Sciences Hits 52-Week Low at $17.53 Amid Ongoing Struggles
USANA Health Sciences, Inc. has reached a new 52-week low, trading at USD 17.53. The company has seen a significant decline in stock price over the past year, with a 61.95% drop. Financial metrics indicate challenges, including seven consecutive quarters of negative results and a market capitalization of USD 396 million.
USANA Health Sciences Hits 52-Week Low at $18.04 Amid Ongoing Struggles
USANA Health Sciences, Inc. has hit a new 52-week low, trading at USD 18.04, following a significant decline in its stock price over the past year. The company has reported negative results for seven consecutive quarters, with declining operating cash flow and net profit, indicating ongoing financial challenges.
USANA Health Sciences Experiences Valuation Adjustment Amidst Competitive Market Dynamics
USANA Health Sciences, Inc. has recently adjusted its valuation, with its stock price at $21.52. Over the past year, the company has experienced a decline of nearly 25%, contrasting with the S&P 500's positive performance. Key financial metrics indicate a competitive landscape within the Pharmaceuticals & Biotechnology sector.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued with a P/E ratio of 16, poor recent performance (-42.74% year-to-date and -73.15% over five years), especially compared to its peers like Chromadex Corp. and Nature's Sunshine Products, Inc.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of October 31, 2025, USANA Health Sciences, Inc. is considered overvalued with a valuation grade of very expensive, a P/E ratio of 16, and less favorable returns compared to peers and the S&P 500.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued due to its lower P/E and EV to EBITDA ratios compared to peers, alongside significant underperformance against the S&P 500.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued despite a lower P/E ratio compared to some peers, with significant underperformance relative to the S&P 500, showing a year-to-date return of -41.07% and a three-year return of -59.72%.
USANA Health Sciences Experiences Revision in Stock Evaluation Amid Market Challenges
USANA Health Sciences, Inc. has recently revised its market evaluation, with its stock priced at $29.69. Over the past year, the company has faced challenges, showing a significant decline compared to the S&P 500. Technical indicators present a mixed outlook, reflecting potential volatility in its performance.
Is USANA Health Sciences, Inc. technically bullish or bearish?
As of September 19, 2025, USANA Health Sciences, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with year-to-date and one-year returns of -17.28% and -23.08%, respectively.
Is USANA Health Sciences, Inc. technically bullish or bearish?
As of September 19, 2025, USANA Health Sciences, Inc. exhibits a bearish trend with moderate strength, indicated by daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD and no momentum signals from the RSI.
Is USANA Health Sciences, Inc. technically bullish or bearish?
As of September 11, 2025, USANA Health Sciences, Inc. shows a mildly bearish trend overall, with mixed signals from technical indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -14.07%.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of August 6, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued, with a P/E ratio of 16, an EV to EBITDA ratio of 4.61, and disappointing stock performance, including a YTD return of -14.07% and a 5-year return of -59.08%.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of June 27, 2025, USANA Health Sciences, Inc. is fairly valued with a P/E ratio of 16, an EV to EBITDA of 4.61, and a ROCE of 15.36%, lagging behind the S&P 500 with a year-to-date return of -13.26%.
Is USANA Health Sciences, Inc. overvalued or undervalued?
As of October 1, 2023, USANA Health Sciences, Inc. is considered attractive and undervalued with a P/E ratio of 15.2, outperforming the Sensex and trading at a discount compared to Herbalife's P/E of 18.4, while slightly exceeding Nature's Sunshine's P/E of 14.7.
Is USANA Health Sciences, Inc. technically bullish or bearish?
As of November 1, 2023, there is insufficient technical data to assess the current stance of USANA Health Sciences, Inc.
Who are in the management team of USANA Health Sciences, Inc.?
As of March 2022, the management team of USANA Health Sciences, Inc. includes Chairman and CEO Kevin Guest, Lead Independent Director Gilbert Fuller, Senior Director Robert Anciaux, Director John Fleming, and Independent Directors Peggie Pelosi and Feng Peng. They oversee the company's strategic direction and operations.
What does USANA Health Sciences, Inc. do?
USANA Health Sciences, Inc. develops and manufactures nutritional and personal care products, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $250 million and a market cap of $567.07 million.
How big is USANA Health Sciences, Inc.?
As of Jun 18, USANA Health Sciences, Inc. has a market capitalization of 567.07 million and net sales of 876.24 million with a net profit of 34.81 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
